v3.26.1
Business and Principal Activities (Additional Information) (Details) - USD ($)
$ in Thousands
3 Months Ended
Nov. 14, 2025
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Proceeds from equity financing, net of issuance cost   $ 81,400    
Cash and cash equivalents   12,362   $ 7,024
Net loss   (3,521) $ (2,420)  
Accumulated deficit   (64,908)   $ (61,387)
Maximum possible proceeds from offerings $ 50,000      
Revenues   563 $ 197  
RenovoRx, Inc. [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue from Contract with Customer, Including Assessed Tax   $ 1,100